Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	18.77	-187.35	-152.99	-104.68	-58.74	-45.36
Depreciation & Amortization	1.36	1.23	0.82	0.67	0.38	0.28
Loss (Gain) From Sale of Assets	-0.01	-	0	0.01	0.05	-
Stock-Based Compensation	35.42	34.87	28.76	18.68	11.72	4.1
Other Operating Activities	2.31	1.82	1.55	0.94	0.52	1.82
Change in Accounts Receivable	-15.81	-2.6	-0.14	18	-18	-
Change in Accounts Payable	-1.23	-0.25	1.61	-0.41	1.49	0.06
Change in Unearned Revenue	0.93	-	-	-	-	-
Change in Other Net Operating Assets	6.99	-8.59	-4.12	-3.28	0.45	2.21
Operating Cash Flow	55.04	-160.87	-124.51	-70.06	-62.15	-36.89
Capital Expenditures	-1.96	-1.93	-2.46	-1.24	-1.02	-0.29
Investing Cash Flow	-1.96	-1.93	-2.46	-1.24	-1.02	-0.29
Issuance of Common Stock	231.64	392.28	179.05	120.4	28.55	259.94
Other Financing Activities	-0.13	-0.45	-0.09	-0.09	-	-19.89
Financing Cash Flow	231.51	391.82	178.96	120.31	28.55	296.04
Net Cash Flow	284.59	229.02	51.98	49.01	-34.62	258.86
Free Cash Flow	53.08	-162.8	-126.97	-71.3	-63.17	-37.19
Free Cash Flow Margin	22.80%	-4585.91%	-84087.42%	-	-314.29%	-
Free Cash Flow Per Share	1.32	-4.35	-4.31	-2.83	-2.71	-2.40
Levered Free Cash Flow	31.6	-108.31	-81.25	-33.84	-39.48	-22.38
Unlevered Free Cash Flow	31.6	-108.31	-81.25	-33.84	-39.48	-22.37
Change in Working Capital	-2.82	-11.44	-2.65	14.31	-16.07	2.28

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q